OncoMatch/Clinical Trials/NCT06917573
PALACE: Cemiplimab Trial According to ctDNA Levels
Is NCT06917573 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cemiplimab and Carboplatin for non small cell lung cancer metastatic.
Treatment: Cemiplimab · Carboplatin · Paclitaxel — This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR activating mutation
Patients whose tumors harbor an activating mutation in EGFR...sensitive to available targeted inhibitor therapy
Required: ALK translocation
Patients whose tumors harbor...ALK translocation...sensitive to available targeted inhibitor therapy
Required: ROS1 rearrangement
Patients whose tumors harbor...ROS Proto-Oncogene 1 (ROS1) rearrangements sensitive to available targeted inhibitor therapy
Required: PD-L1 (CD274) PDL1 ≥50% (≥50%)
PDL1 ≥50%
Disease stage
Required: Stage IV, IIIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antineoplastic drugs
Exception: adjuvant or neoadjuvant chemotherapy for early stage is permitted if completed at least 6 months prior to enrolment
no prior systemic anti-cancer therapy
Cannot have received: thoracic radiotherapy
Exception: adjuvant/neoadjuvant radiotherapy with curative intent for non-metastatic disease less than 6 months before enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy [excluded]
Prior treatment with antineoplasic drugs or thoracic radiotherapy for any reason different from the ones specific in the inclusion criteria
Lab requirements
Blood counts
correct hematological function
Kidney function
correct renal function
Liver function
correct hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify